Well, I've improperly explained the difference between the name brand and the generic drugs. I'm on the right path but the explanation is off. Here's what the FDA says.
"FDA still uses the plus-or-minus-twenty-percent test to determine blood serum bioavailability (i.e., the amount of active ingredient in the blood over a period of time has to come within plus-or-minus twenty percent of that which is observed when the innovator’s drug is ingested)" From: Overview of the Hatch-Waxman Act and Its Impact on the Drug Development Process
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment